MetaCap

CalciMedica (CALC) vs Palatin Technologies (PTN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Palatin Technologies (PTN) has outperformed CalciMedica (CALC) over the past year, losing 79.9% versus a loss of 92.3%. CalciMedica is the larger company by market cap ($8.7 million vs $8.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CALC-92.34%PTN-79.93%
+115%+6%-104%
Nov 21, 20251 yearNov 20, 2026
CALC-94.99%PTN-95.82%
+107%+1%-106%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CALC versus PTN key metrics
MetricCALCPTN
Share price$1.26$4.58
Market cap$8.69M$8.16M
1-day change+7.69%-7.10%
YTD return-96.18%-70.22%
1-year return-92.34%-79.93%
5-year return—-99.35%
EPS (TTM)$-4.41$-2.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.83M
Net income (latest FY)$-29.56M$-8.38M
Operating margin—-98.17%
Net margin—-94.88%
52-week high$36.00$31.00
52-week low$1.00$4.51
Distance from 52-week high-96.50%-85.23%
Analyst consensusnonestrong_buy
Avg. price target upside+3868.25%+1068.12%
Average volume80.15K71.93K
Shares outstanding6.90M1.78M
Employees1525
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PTN has outperformed CALC by 12.4 percentage points over the past year.

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

CALC vs PTN FAQ

Which is bigger, CalciMedica or Palatin Technologies?

CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.16M for Palatin Technologies (PTN).

Which stock has performed better over the past year, CALC or PTN?

PTN returned -79.93% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are CalciMedica and Palatin Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons